NSI‑189
Experimental compound studied for depression that may stimulate new nerve cells; not proven in humans.
Pharmacology
Contents
DETAILED OVERVIEW
What is NSI-189?
NSI-189 is an experimental compound studied mainly as a treatment for depression. It is not an approved medicine: in the United States it is at the clinical trial stage, and in the EU it counts as a research chemical. It has been studied mostly in animals, and its effect is not proven in humans.
It is thought to stimulate the formation of new nerve cells in the hippocampus, a brain area linked to memory, but its exact mechanism is unclear. In a study of people with depression it did not produce a significant improvement on the main outcome measure, only on secondary measures and the patients' own reports. It may cause early irritability, insomnia and headache, and its long-term safety is unknown. In bipolar disorder it carries a risk of mania, in active psychosis it may worsen symptoms, and together with certain antidepressants it carries a risk of serotonin syndrome (a dangerous excess of serotonin). There are no safety data for pregnancy or breastfeeding.
Mechanism
Hippocampal neurogenesis
Half-life
17-20 hours
Onset
1-2 weeks (subjective), 4-6 weeks (plateau)
Legal status
USA research, FDA Phase 2
Anecdotal reports describe NSI-189 as exhibiting a hippocampus-centered profile that is unusually promising compared to other nootropic agents, with a bell-shaped dose-response curve meaning higher doses do not necessarily mean stronger effects. Rodent work links the compound to mitochondrial respiratory improvements and spare respiratory capacity. Phase 1B trials showed a 17.4-20.5 hour half-life with steady state in about 4-5 days, alongside benefits to executive function, learning accuracy, and memory-related performance. Community accounts describe emotional restoration rather than artificial elevation, with vivid memory resurfacing being a recurring report. Some users describe heightened sensory texture and reduced social friction, including improvements in treatment-resistant depression symptoms. Benefits are reported to linger after stopping use, consistent with plasticity-driven structural changes rather than acute effects.
⚠ Not clinical evidence – based on user accounts.
Receptor profile
- TLX / NR2E1 nuclear receptorStrong
- Hippocampal neurogenesisStrong
- BDNFModerate
- PI3K/Akt/mTOR signalingModerate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Early irritability, mood agitation (typically in the first week)
- Insomnia, disrupted sleep (avoid late-evening dosing)
- Headache, mild anxiety (anecdotal reports)
- Higher doses (80+ mg) bring more side effects, not stronger benefit (bell-shaped curve)
- Limited human safety data, full side-effect spectrum unknown
- Long half-life (17-20 h) gives cumulative effect, steady state in 4-5 days
Contraindications · 6
- Pregnancy, breastfeeding (no clinical safety data)
- Avoid combining with MAOIs (preclinically untested monoaminergic interaction)
- SSRI/SNRI combination only under medical supervision (serotonin syndrome risk)
- Bipolar spectrum: mania risk, medical monitoring required
- Active psychotic disorder (neurogenesis-inducing mechanism may worsen symptoms)
- Caution with CNS depressants (alcohol, benzodiazepines); not FDA-approved, unknown long-term safety
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats.
Tajiri N, Quach DM, Kaneko Y, et al.
The neurogenic compound NSI-189 phosphate: pro-cognitive and antidepressant effects (review)
Papakostas GI et al.
FAQ
FAQ
NSI-189 is an experimental, still-researched substance that has mainly been studied in clinical trials for depression, with the unusual feature that it is said to stimulate regrowth in the brain's memory-related region, the hippocampus. Trials have observed benefits for mood as well as cognitive functions like memory and learning, and interestingly the effects may persist after stopping the treatment, since the change is described as structural rather than immediate. Because this is still a substance in development rather than an approved medicine, human experience with it remains limited to clinical trial settings.
Telegram
Have a question about NSI‑189?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.